logo

Axcella Health Inc (AXLA)



Trade AXLA now with
  Date
  Headline
9/29/2022 6:09:32 AM Axcella Announces Positive Interim Data From Phase 2b EMMPACT Study Of AXA1125 In Nonalcoholic Steatohepatitis
8/12/2022 7:33:45 AM Axcella Therapeutics Q2 Net Loss/shr $0.40 Vs. Loss/shr $0.42 Last Year
8/2/2022 6:11:16 AM Axcella Reports Highly Promising Results From Phase 2a Placebo Controlled Clinical Trial For Long COVID
5/5/2022 7:15:12 AM Axcella Therapeutics Q1 Net Loss $19.0 Mln Or $0.46/shr Vs Net Loss Of $15.2 Mln Or $0.40/shr Prior Year
6/30/2021 7:46:13 AM Axcella Initiates Phase 2 Trial Of AXA1665, Oral Product Candidate For Reduction In Risk Of Recurrent OHE
5/24/2021 7:29:56 AM Axcella Presents Positive Data From AXA1665-002 Clinical Study At Digestive Disease Week 2021 Annual Meeting
5/19/2021 9:45:37 AM Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening
5/11/2021 8:01:03 AM Axcella Begins EMMPACT Phase 2b Clinical Trial Of AXA1125
5/11/2021 7:39:12 AM Axcella Begins EMMPACTSM Phase 2b Clinical Trial Of AXA1125
4/13/2021 7:31:10 AM Axcella Says AXA1125's IND Clearance For NASH, Enabling The Company To Proceed Directly Into Phase 2b Clinical Trial
3/17/2021 7:36:05 AM Axcella Q4 Net Loss $15.2 Mln Or $0.40/shr Vs. Loss $15.7 Mln Or $0.68/shr Prior Year
1/11/2021 8:32:47 AM Axcella Reports IND Clearance For AXA1665